Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Clinical Research and Equipment Industry Analysis

UpdatedAug 14, 2025
DataAggregated Company Financials
Companies64
  • 7D7.9%
  • 3M14.6%
  • 1Y-19.0%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has risen 7.9%, driven by gains from Thermo Fisher Scientific of 6.7%. Meanwhile, Stevanato Group actually underperformed within the industry, shrinking 8.4% in the last week. However, the industry is down 19% over the past year. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 15 Aug 2025US$568.9bUS$144.2bUS$14.4b30.4x39.5x3.9x
Sun, 13 Jul 2025US$551.6bUS$142.9bUS$9.1b36.9x60.4x3.9x
Tue, 10 Jun 2025US$518.8bUS$142.9bUS$9.2b35.7x56.6x3.6x
Thu, 08 May 2025US$501.3bUS$142.7bUS$9.6b34.6x52.2x3.5x
Sat, 05 Apr 2025US$545.7bUS$142.5bUS$9.9b33.4x54.9x3.8x
Mon, 03 Mar 2025US$605.3bUS$143.3bUS$9.7b38.1x62.3x4.2x
Wed, 29 Jan 2025US$709.3bUS$142.4bUS$10.2b45.5x69.5x5x
Fri, 27 Dec 2024US$658.4bUS$142.4bUS$10.2b44.8x64.4x4.6x
Sun, 24 Nov 2024US$656.8bUS$142.4bUS$10.4b44.1x63.4x4.6x
Tue, 22 Oct 2024US$736.3bUS$141.8bUS$8.5b37x86.7x5.2x
Thu, 19 Sep 2024US$739.5bUS$141.8bUS$8.5b37.5x87x5.2x
Sat, 17 Aug 2024US$737.8bUS$141.5bUS$8.4b38.8x88.2x5.2x
Mon, 15 Jul 2024US$685.9bUS$141.2bUS$12.2b40.7x56.2x4.9x
Wed, 12 Jun 2024US$712.9bUS$141.3bUS$12.2b37.4x58.5x5x
Fri, 10 May 2024US$713.4bUS$141.6bUS$12.6b39.3x56.4x5x
Sun, 07 Apr 2024US$727.9bUS$142.1bUS$12.8b43.1x56.9x5.1x
Tue, 05 Mar 2024US$747.1bUS$142.2bUS$12.8b44.5x58.3x5.3x
Thu, 01 Feb 2024US$719.4bUS$148.2bUS$12.5b38.4x57.6x4.9x
Sat, 30 Dec 2023US$706.1bUS$153.8bUS$14.2b37.8x49.6x4.6x
Mon, 27 Nov 2023US$642.9bUS$153.8bUS$14.0b34.7x45.9x4.2x
Wed, 25 Oct 2023US$604.8bUS$154.6bUS$11.2b31.1x54x3.9x
Fri, 22 Sep 2023US$671.1bUS$154.6bUS$11.2b31.3x59.9x4.3x
Sun, 20 Aug 2023US$702.8bUS$154.6bUS$11.2b32.5x62.7x4.5x
Tue, 18 Jul 2023US$706.1bUS$155.5bUS$12.7b29.5x55.7x4.5x
Thu, 15 Jun 2023US$690.5bUS$152.4bUS$12.5b29.2x55.2x4.5x
Sat, 13 May 2023US$676.5bUS$152.4bUS$12.7b28.7x53.2x4.4x
Mon, 10 Apr 2023US$719.8bUS$154.6bUS$10.8b30x66.6x4.7x
Wed, 08 Mar 2023US$717.2bUS$154.5bUS$10.9b30.4x65.9x4.6x
Fri, 03 Feb 2023US$780.5bUS$155.8bUS$9.1b32.6x86x5x
Sun, 01 Jan 2023US$761.5bUS$155.2bUS$8.8b29.1x86.7x4.9x
Tue, 29 Nov 2022US$752.4bUS$155.1bUS$8.8b28x85.6x4.9x
Thu, 27 Oct 2022US$722.5bUS$154.5bUS$17.1b27.6x42.3x4.7x
Sat, 24 Sep 2022US$713.7bUS$152.2bUS$17.3b25.5x41.2x4.7x
Mon, 22 Aug 2022US$817.8bUS$152.3bUS$17.3b31.1x47.2x5.4x
Price to Earnings Ratio

47.2x


Total Market Cap: US$817.8bTotal Earnings: US$17.3bTotal Revenue: US$152.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Clinical Research and Equipment Industry Price to Earnings3Y Average 62x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 39.5x which is lower than its 3-year average PE of 62.0x.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 6.0% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does U.S. Clinical Research and Equipment compare with similar industries?

US Market1.92%
Healthcare2.51%
Life Sciences7.93%
Clinical Research and Equipment7.93%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$485.046.7%
+US$11.4b		-19.7%PE27.8x
DHR DanaherUS$210.225.9%
+US$8.4b		-21.9%PE44.1x
TEM Tempus AIUS$71.5921.9%
+US$2.3b		51.7%PS13.1x
IQV IQVIA HoldingsUS$189.405.8%
+US$1.8b		-21.4%PE26x
MTD Mettler-Toledo InternationalUS$1.31k6.2%
+US$1.6b		-8.4%PE32.6x

Latest News

RPID
US$2.82
Rapid Micro Biosystems
7D
-15.8%
1Y
239.5%
LAB
US$1.22
Standard BioTools
7D
-5.4%
1Y
-32.2%
SHC
US$15.76
Sotera Health
7D
40.5%
1Y
6.8%

After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar

Aug 13
After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar
DNA
US$12.90
Ginkgo Bioworks Holdings
7D
-4.2%
1Y
26.7%
TMO
US$485.04
Thermo Fisher Scientific
7D
6.7%
1Y
-19.7%
ICLR
US$175.36
ICON
7D
11.1%
1Y
-45.5%

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 43%?

Aug 12
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 43%?
DHR
US$210.22
Danaher
7D
5.9%
1Y
-21.9%
LFCR
US$7.42
Lifecore Biomedical
7D
-4.4%
1Y
24.1%
PACB
US$1.23
Pacific Biosciences of California
7D
-2.4%
1Y
-27.2%
TEM
US$71.59
Tempus AI
7D
21.9%
1Y
51.7%
NOTV
US$1.84
Inotiv
7D
-6.1%
1Y
20.3%
STVN
US$22.17
Stevanato Group
7D
-8.4%
1Y
10.9%

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
A
US$118.87
Agilent Technologies
7D
4.3%
1Y
-15.0%

Agilent: A Lean, Focused Play In Life Sciences Tools Amid Tariff Turbulence

Aug 08
MTD
US$1,313.64
Mettler-Toledo International
7D
6.2%
1Y
-8.4%
IQV
US$189.40
IQVIA Holdings
7D
5.8%
1Y
-21.4%
QSI
US$1.17
Quantum-Si
7D
-14.6%
1Y
32.9%

Quantum-Si Stock: A Small Position Is Warranted (Technical Analysis)

Jul 23